CLOVIS ONCOLOGY INC's ticker is CLVS and the CUSIP is 189464100. A total of 146 filers reported holding CLOVIS ONCOLOGY INC in Q4 2014. The put-call ratio across all filers is 0.43 and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $270,000 | -35.4% | 9,184 | 0.0% | 0.02% | -54.5% |
| Q2 2018 | $418,000 | -13.8% | 9,184 | 0.0% | 0.03% | +13.8% |
| Q1 2018 | $485,000 | -22.4% | 9,184 | 0.0% | 0.03% | -29.3% |
| Q4 2017 | $625,000 | -17.4% | 9,184 | 0.0% | 0.04% | +7.9% |
| Q3 2017 | $757,000 | -12.0% | 9,184 | 0.0% | 0.04% | -17.4% |
| Q2 2017 | $860,000 | +47.0% | 9,184 | 0.0% | 0.05% | +15.0% |
| Q1 2017 | $585,000 | +186.8% | 9,184 | +100.0% | 0.04% | +185.7% |
| Q4 2016 | $204,000 | -51.7% | 4,592 | 0.0% | 0.01% | -54.8% |
| Q3 2015 | $422,000 | -66.3% | 4,592 | -67.7% | 0.03% | -64.4% |
| Q2 2015 | $1,251,000 | +224.9% | 14,235 | +67.6% | 0.09% | +222.2% |
| Q3 2014 | $385,000 | +9.4% | 8,495 | 0.0% | 0.03% | +12.5% |
| Q2 2014 | $352,000 | -40.1% | 8,495 | 0.0% | 0.02% | -36.8% |
| Q1 2014 | $588,000 | -31.5% | 8,495 | -40.3% | 0.04% | -29.6% |
| Q4 2013 | $858,000 | -0.8% | 14,235 | 0.0% | 0.05% | 0.0% |
| Q3 2013 | $865,000 | -9.2% | 14,235 | 0.0% | 0.05% | -3.6% |
| Q2 2013 | $953,000 | – | 14,235 | – | 0.06% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 3,402,781 | $231,389,000 | 9.96% |
| Versant Venture Management, LLC | 101,855 | $6,926,140,000 | 7.29% |
| Avoro Capital Advisors LLC | 1,102,884 | $74,996,000 | 4.86% |
| Redmile Group, LLC | 1,320,027 | $89,762,000 | 3.90% |
| NEXTHERA CAPITAL LP | 233,200 | $15,858,000 | 2.92% |
| Iguana Healthcare Management, LLC | 60,000 | $4,080,000 | 2.66% |
| HealthCor Management, L.P. | 973,840 | $66,221,000 | 2.16% |
| Casdin Capital, LLC | 127,500 | $8,670,000 | 2.11% |
| Prosight Management, LP | 40,000 | $2,720,000 | 2.00% |
| Camber Capital Management LP | 600,000 | $40,800,000 | 2.00% |